Both in Diagnostics
Myriad Genetics vs Immucell
Over the past year MYGN returned −27.0% and ICCC returned +63.6%; their daily moves had a correlation of -0.01.
MYGN −27.0% ICCC +63.6%Growth of $1, one year, split-adjusted
| Metric | MYGN | ICCC |
|---|---|---|
| Price | $5.97 | $10.16 |
| Market cap | $571.0M | $92.3M |
| Today | −1.16% | −0.88% |
| 1 month | +39.5% | +1.9% |
| 6 months | +45.3% | +17.3% |
| Year to date | −2.9% | +65.2% |
| 1 year | −27.0% | +63.6% |
| Revenue growth (YoY) | −10.5% | +11.5% |
| Gross margin | 66.6% | 33.9% |
| Net margin | −22.7% | 25.5% |
| P/E (TTM) | — | 117.2× |
| Price / sales | 0.7× | 3.0× |
| Net cash | -$5.5M | $557.3K |
| Dividend yield | — | — |
| Volatility (60d) | 85.1% | 38.4% |
| Short % of float | 10.1% | 0.3% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).